MA37998A1 - Anti-cd3 antibodies, bispecific antigen binding molecules that bind to cd3 and cd20, and their uses - Google Patents

Anti-cd3 antibodies, bispecific antigen binding molecules that bind to cd3 and cd20, and their uses

Info

Publication number
MA37998A1
MA37998A1 MA37998A MA37998A MA37998A1 MA 37998 A1 MA37998 A1 MA 37998A1 MA 37998 A MA37998 A MA 37998A MA 37998 A MA37998 A MA 37998A MA 37998 A1 MA37998 A1 MA 37998A1
Authority
MA
Morocco
Prior art keywords
antibodies
bind
binding molecules
bispecific antigen
human
Prior art date
Application number
MA37998A
Other languages
French (fr)
Other versions
MA37998B2 (en
Inventor
Nicholas J Papadopoulos
Eric Smith
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2013/060511 external-priority patent/WO2014047231A1/en
Publication of MA37998A1 publication Critical patent/MA37998A1/en
Publication of MA37998B2 publication Critical patent/MA37998B2/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps qui se lient à cd3 et des procédés d'utilisation de ceux-ci. Selon certains modes de réalisation, les anticorps de l'invention se lient à cd3 humain à affinité élevée et induisent la prolifération de lymphocytes t humains. L'invention comprend des anticorps qui se lient à cd3 et induisent la mort à médiation par des lymphocytes t de cellules tumorales. Selon certains modes de réalisation, la présente invention concerne des molécules de liaison à un antigène bispécifiques, comprenant un premier domaine de liaison à un antigène qui se lie spécifiquement au cd3 humain, et une seconde molécule de liaison à un antigène qui se lie spécifiquement au cd20 humain. Dans certains modes de réalisation, les molécules de liaison à un antigène bispécifiques de la présente invention sont aptes à inhiber la croissance de tumeurs à cellules b exprimant cd20. Les anticorps et molécules de liaison à un antigène bispécifiques de l'invention sont utiles pour le traitement de maladies et de troubles dans lesquels une réponse immunitaire ciblée, régulée à la hausse ou induite, est souhaitée et/ou bénéfique thérapeutiquement. Par exemple, les anticorps de l'invention sont utiles pour le traitement de divers cancers, ainsi que d'autres maladies et troubles associés à cd20.The present invention relates to antibodies that bind to cd3 and methods of using the same. In some embodiments, the antibodies of the invention bind to high affinity human cd3 and induce proliferation of human t cells. The invention includes antibodies that bind to cd3 and induce tumor cell-mediated death of tumor cells. In some embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds to human cd3, and a second antigen-binding molecule that specifically binds to human cd20. In some embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of cd20 expressing b-cell tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which a targeted, upregulated or induced immune response is desired and / or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers, as well as other diseases and disorders associated with cd20.

MA37998A 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses MA37998B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261704029P 2012-09-21 2012-09-21
PCT/US2013/060511 WO2014047231A1 (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Publications (2)

Publication Number Publication Date
MA37998A1 true MA37998A1 (en) 2017-07-31
MA37998B2 MA37998B2 (en) 2020-07-29

Family

ID=59745478

Family Applications (2)

Application Number Title Priority Date Filing Date
MA37998A MA37998B2 (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses
MA41873A MA41873B2 (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA41873A MA41873B2 (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof

Country Status (1)

Country Link
MA (2) MA37998B2 (en)

Also Published As

Publication number Publication date
MA37998B2 (en) 2020-07-29
MA41873B2 (en) 2022-04-29
MA41873A1 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
MA42935B1 (en) Optimized anti-cd3 bispecific antibodies and their uses
MA49043B1 (en) STABLE ANTIBODY FORMULATION
EA201990781A9 (en) ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION
EP4309740A3 (en) Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
JOP20160154B1 (en) Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
MA44312A (en) ANTIBODIES AND THEIR METHODS OF USE
EA201691858A1 (en) ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS
MA42542B1 (en) Molecules Binding to pd-1 and Corresponding Methods of Use
MA43327A1 (en) Peptides and peptide combination for use in immunotherapy against non-small cell lung cancer and other cancers
MA43328A1 (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
MA44101A (en) PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS
MA46022A (en) NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS
EA201490957A1 (en) TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES WITH ANTI-CXCR4 ANTIBODY
MA40041A (en) ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
MA43458A1 (en) Novel peptides, peptide combinations and carriers for use in the immunotherapeutic treatment of various cancers
MA33402B1 (en) COMPOSITIONS AND METHODS FOR TARGETING COMPLEMENT C3B PROTEIN BY ANTIBODIES
MX2020008445A (en) Methods for treating cancer with anti-pd-1 antibodies.
MA33387B1 (en) POLYPEPTIDES AND PROCESSING METHOD
MA37998A1 (en) Anti-cd3 antibodies, bispecific antigen binding molecules that bind to cd3 and cd20, and their uses
MA42523B1 (en) Anti-psma antibodies, bispecific antigen-binding molecules which bind psma and cd3 and uses thereof
MX2021008453A (en) Formulations of antibodies that bind human cd137 and uses thereof.
MA39751B1 (en) Antibody compositions for the treatment of tumors
MA46281B1 (en) Anti-muc16 antibodies (mucin 16)
MA39202B1 (en) Human antibodies against pd-l1
EA202190314A1 (en) BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES AND METHODS OF THEIR APPLICATION